Metabolites in Safety Testing (MIST): Considerations of Mechanisms of Toxicity with Dose, Abundance, and Duration of Treatment

被引:103
|
作者
Smith, Dennis A. [1 ]
Obach, R. Scott [2 ]
机构
[1] Pfizer Inc, Pharmacokinet Dynam & Metab, Sandwich, Kent, England
[2] Pfizer Inc, Dynam & Metab, Groton, CT 06340 USA
关键词
HUMAN LIVER-MICROSOMES; HUMAN UDP-GLUCURONOSYLTRANSFERASES; AMMONIUM-LINKED GLUCURONIDATION; RECEPTOR ANTAGONIST CP-122,721; ALDEHYDE OXIDASE ACTIVITY; IN-VITRO; SPECIES-DIFFERENCES; N-GLUCURONIDATION; DRUG-METABOLISM; PARTIAL AGONIST;
D O I
10.1021/tx800415j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In previous papers, we have offered a strategic framework regarding metabolites of drugs in humans and the need to assess these in laboratory animal species (also termed Metabolites in Safety Testing or MIST; Smith and Obach, Chem. Res. Toxicol. (2006) 19, 1570-1579). Three main tenets of this framework were founded in (i) comparisons of absolute exposures (as circulating concentrations or total body burden), (ii) the nature of the toxicity mechanism (i.e., reversible interaction at specific targets versus covalent binding to multiple macromolecules), and (iii) the biological matrix in which the metabolite was observed (circulatory vs excretory). In the present review, this framework is expanded to include a fourth tenet: considerations for the duration of exposure. Basic concepts of pharmacology are utilized to rationalize the relationship between exposure (to parent drug or metabolite) and various effects ranging from desired therapeutic effects through to severe toxicities. Practical considerations of human ADME (absorption-distribution-metabolism-excretion) data, to determine which metabolites should be further evaluated for safety, are discussed. An analysis of recently published human ADME studies shows that the number of drug metabolites considered to be important for MIST can be excessively high if a simple percentage-of-parent-drug criterion is used without consideration of the aforementioned four tenets. Concern over unique human metabolites has diminished over the years as experience has shown that metabolites of drugs in humans will almost always be observed in laboratory animals, although the proportions may vary. Even if a metabolite represents a high proportion of the dose in humans and a low proportion in animals, absolute abundances in animals frequently exceed that in humans because the doses used in animal toxicology studies are much greater than therapeutic doses in humans. The review also updates the enzymatic basis for the differences between species and how these relate to MIST considerations.
引用
收藏
页码:267 / 279
页数:13
相关论文
共 31 条
  • [1] Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity
    Smith, Dennis A.
    Obach, R. Scott
    Williams, Dominic P.
    Park, B. Kevin
    CHEMICO-BIOLOGICAL INTERACTIONS, 2009, 179 (01) : 60 - 67
  • [2] Seeing through the mist:: Abundance versus percentage.: Commentary on Metabolites in safety testing
    Smith, DA
    Obach, RS
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (10) : 1409 - 1417
  • [3] Metabolites in Safety Testing: "MIST" for the Clinical Pharmacologist
    Frederick, C. B.
    Obach, R. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) : 345 - 350
  • [4] Introduction: Human Metabolites in Safety Testing (MIST) Issue
    Guengerich, F. Peter
    CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (02) : 237 - 238
  • [5] LEVERAGING ADME DATA IN METABOLITES IN SAFETY TESTING (MIST)
    Smith, Dennis Allen
    Obach, R. Scott
    DRUG METABOLISM REVIEWS, 2007, 39 : 31 - 31
  • [6] CONSIDERATIONS IN CHRONIC TOXICITY TESTING - CHEMICAL, THE DOSE, THE DESIGN
    MUNRO, IC
    JOURNAL OF ENVIRONMENTAL PATHOLOGY AND TOXICOLOGY, 1977, 1 (02) : 183 - 197
  • [7] Amiodarone pulmonary toxicity - Dose and duration of treatment are not the only determinants of toxicity
    Jessurun, GAJ
    Crijns, HJGM
    BRITISH MEDICAL JOURNAL, 1997, 314 (7081): : 619 - 620
  • [8] E-waste: mechanisms of toxicity and safety testing
    Eze, Chukwuebuka
    Vinken, Mathieu
    FEBS OPEN BIO, 2024, 14 (09): : 1420 - 1440
  • [9] Why I love metabolites in safety testing (MIST): a light-hearted historical perspective
    Tonelli, Alfred
    BIOANALYSIS, 2009, 1 (04) : 683 - 685
  • [10] A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory Guidance
    Schadt, Simone
    Bister, Bojan
    Chowdhury, Swapan K.
    Funk, Christoph
    Hop, Cornelis E. C. A.
    Humphreys, W. Griffith
    Igarashi, Fumihiko
    James, Alexander D.
    Kagan, Mark
    Khojasteh, S. Cyrus
    Nedderman, Angus N. R.
    Prakash, Chandra
    Runge, Frank
    Scheible, Holger
    Spracklin, Douglas K.
    Swart, Piet
    Tse, Susanna
    Yuan, Josh
    Obach, R. Scott
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (06) : 865 - 878